PSMA-RADS 版本 1.0：迈向 PSMA 靶向 PET 成像研究解读和报告标准化的一步。
PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies.
机构信息
The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
出版信息
Eur Urol. 2018 Apr;73(4):485-487. doi: 10.1016/j.eururo.2017.10.027. Epub 2017 Nov 11.
Abstract
The use of [F]- and [Ga]-labeled inhibitors of prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of prostate cancer is now widespread. We have proposed a reporting and data system called PSMA-RADS version 1.0, which is a framework for classifying PSMA-targeted PET scans and individual findings into categories that reflect the likelihood of the presence of prostate cancer.
摘要
目前，使用 [F]-和 [Ga]-标记的前列腺特异性膜抗原（PSMA）抑制剂进行正电子发射断层扫描（PET）成像来诊断前列腺癌已经较为广泛。我们提出了一种称为 PSMA-RADS 版本 1.0 的报告和数据系统，该系统是一种将 PSMA 靶向 PET 扫描和各个发现分类为反映前列腺癌存在可能性的类别框架。
相似文献
1
PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies.PSMA-RADS 版本 1.0：迈向 PSMA 靶向 PET 成像研究解读和报告标准化的一步。
Eur Urol. 2018 Apr;73(4):485-487. doi: 10.1016/j.eururo.2017.10.027. Epub 2017 Nov 11.
2
Simultaneous Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer.镓-PSMA HBED-CC PET/MRI 联合检查可提高前列腺癌原发灶的定位诊断。
Eur Urol. 2016 Nov;70(5):829-836. doi: 10.1016/j.eururo.2015.12.053. Epub 2016 Jan 18.
3
Diagnostic Performance of Ga Prostate-specific Membrane Antigen PET/MRI Compared with Multiparametric MRI for Detecting Clinically Significant Prostate Cancer.镓前列腺特异性膜抗原 PET/MRI 与多参数 MRI 检测临床显著前列腺癌的诊断性能比较。
Radiology. 2021 Nov;301(2):379-386. doi: 10.1148/radiol.2021204093. Epub 2021 Aug 31.
4
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
5
Diagnostic Accuracy of Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer.镓-PSMA-11 PET/MRI 与多参数 MRI 检测前列腺癌的诊断准确性比较。
Radiology. 2018 Dec;289(3):730-737. doi: 10.1148/radiol.2018180788. Epub 2018 Sep 18.
6
Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer.镓-PSMA-PET：与当前在前列腺癌检查中使用胆碱-PET 和 mpMRI 相比的附加价值和未来应用。
Radiol Med. 2018 Dec;123(12):952-965. doi: 10.1007/s11547-018-0929-9. Epub 2018 Aug 16.
7
Improving Diagnosis of Primary Prostate Cancer With Combined Ga-Prostate-Specific Membrane Antigen-HBED-CC Simultaneous PET and Multiparametric MRI and Clinical Parameters.同时进行 Ga-前列腺特异性膜抗原-HBED-CC 联合正电子发射断层扫描和多参数磁共振成像以及临床参数检查以提高原发性前列腺癌的诊断率。
AJR Am J Roentgenol. 2018 Dec;211(6):1246-1253. doi: 10.2214/AJR.18.19585. Epub 2018 Oct 9.
8
F-labeled 1,2,3-triazole-linked Glu-urea-Lys-based PSMA ligands have good pharmacokinetic properties for positron emission tomography imaging of prostate cancer.F-标记的 1,2,3-三唑连接的 Glu-urea-Lys 基 PSMA 配体具有良好的前列腺癌正电子发射断层扫描成像的药代动力学特性。
Prostate. 2020 Dec;80(16):1383-1393. doi: 10.1002/pros.24062. Epub 2020 Sep 22.
9
68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer.68Ga 标记的前列腺特异性膜抗原（PSMA）抑制剂用于前列腺癌成像。
J Med Chem. 2010 Jul 22;53(14):5333-41. doi: 10.1021/jm100623e.
10
Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.18F-氟甲基胆碱与 68Ga-PSMA PET/CT 在经治愈性治疗后 PSA 升高且正在考虑靶向治疗的前列腺癌患者中的前瞻性比较。
J Nucl Med. 2015 Aug;56(8):1185-90. doi: 10.2967/jnumed.115.160382. Epub 2015 Jun 25.
引用本文的文献
1
Advanced Image Analysis to Select Patients for Prostate Specific Membrane Antigen Radioligand Therapy and Assess Treatment Response.采用先进图像分析技术选择前列腺特异性膜抗原放射性配体治疗的患者并评估治疗反应。
Adv Radiat Oncol. 2025 May 10;10(8):101805. doi: 10.1016/j.adro.2025.101805. eCollection 2025 Aug.
2
PSMA-RADS 2.0: a revised framework for PSMA-targeted imaging interpretation and clinical decision-making.前列腺特异性膜抗原（PSMA）影像报告和数据系统（PSMA-RADS）2.0：PSMA靶向成像解读与临床决策的修订框架
Abdom Radiol (NY). 2025 Jun 14. doi: 10.1007/s00261-025-05068-7.
3
Biphasic contrast-enhanced [F]PSMA-1007 PET/CT imaging to improve the detection of local relapse of prostate cancer.双相对比增强[F]PSMA - 1007 PET/CT成像以提高前列腺癌局部复发的检测率
EJNMMI Res. 2025 May 30;15(1):61. doi: 10.1186/s13550-025-01252-4.
4
PSMA PET Imaging in the Management of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radioligand Therapy.PSMA正电子发射断层显像在接受放射性配体治疗的转移性去势抵抗性前列腺癌患者管理中的应用
Target Oncol. 2025 May 26. doi: 10.1007/s11523-025-01151-7.
5
Comparison of Prostate-specific Membrane Antigen Reporting and Data System Version 1.0 versus 2.0 for Prostate Cancer Assessment.用于前列腺癌评估的前列腺特异性膜抗原报告与数据系统1.0版和2.0版的比较
Radiol Imaging Cancer. 2025 May;7(3):e240390. doi: 10.1148/rycan.240390.
6
Comparative Evaluation of ( F)AlF-PSMA-HBED-CC and Ga-PSMA-HBED-CC in Staging Intermediate-/High-Risk Prostate Cancer: A Prospective Study.(18F)AlF-PSMA-HBED-CC与68Ga-PSMA-HBED-CC在中/高危前列腺癌分期中的比较评估：一项前瞻性研究
World J Nucl Med. 2025 Jan 21;24(2):118-127. doi: 10.1055/s-0045-1801842. eCollection 2025 Jun.
7
[F]PSMA-1007 PET/MR as a Precision Biomarker for Early Detection of Biochemical Recurrence in Prostate Cancer at Very Low PSA Levels.[F]PSMA - 1007正电子发射断层扫描/磁共振成像作为极低前列腺特异抗原水平下前列腺癌生化复发早期检测的精准生物标志物
Biomark Insights. 2025 Mar 12;20:11772719251324307. doi: 10.1177/11772719251324307. eCollection 2025.
8
The prognostic role of staging [18F]PSMA-1007 PET/CT volumetric and dissemination features in prostate cancer.[18F]PSMA - 1007 PET/CT体积及播散特征分期在前列腺癌中的预后作用
Ann Nucl Med. 2025 May;39(5):518-526. doi: 10.1007/s12149-025-02026-7. Epub 2025 Feb 17.
9
Impact of delayed pelvic imaging on the staging of biochemical recurrence in prostate cancer patients using [F]DCFPYL PET/CT: a retrospective evaluation.延迟盆腔成像对使用[F]DCFPYL PET/CT的前列腺癌患者生化复发分期的影响：一项回顾性评估
EJNMMI Rep. 2025 Feb 1;9(1):5. doi: 10.1186/s41824-025-00238-8.
10
Which PSMA PET/CT interpretation criteria most effectively diagnose prostate cancer? a retrospective cohort study.哪种PSMA PET/CT解读标准能最有效地诊断前列腺癌？一项回顾性队列研究。
BMC Med Imaging. 2025 Jan 20;25(1):23. doi: 10.1186/s12880-025-01557-9.
本文引用的文献
1
Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen-Targeted PET Imaging: PSMA-RADS Version 1.0.前列腺特异性膜抗原靶向PET成像结构化报告系统提案：PSMA-RADS 1.0版
J Nucl Med. 2018 Mar;59(3):479-485. doi: 10.2967/jnumed.117.195255. Epub 2017 Sep 8.
2
Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.前列腺特异性膜抗原（PSMA）靶向 PET 成像的临床解读要点及陷阱。
Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2117-2136. doi: 10.1007/s00259-017-3780-7. Epub 2017 Aug 1.
3
Radiologists May Now Be Accountable for Containing Medicare Costs and Spending Under MACRA.根据《医疗保险获取与责任法案》（MACRA），放射科医生现在可能要对控制医疗保险成本和支出负责。
J Am Coll Radiol. 2017 Oct;14(10):1298-1300. doi: 10.1016/j.jacr.2017.02.042. Epub 2017 Apr 14.
4
"Gotta Catch 'em All", or Do We? Pokemet Approach to Metastatic Prostate Cancer.“全都收服”，还是说我们不这么做？以口袋妖怪为方法治疗转移性前列腺癌。
Eur Urol. 2017 Jul;72(1):1-3. doi: 10.1016/j.eururo.2017.02.036. Epub 2017 Mar 7.
5
Correlation of PSMA-Targeted F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer.PSMA靶向的F-DCFPyL PET/CT检查结果与转移性神经内分泌前列腺癌患者免疫组织化学及基因组数据的相关性
Clin Genitourin Cancer. 2017 Feb;15(1):e65-e68. doi: 10.1016/j.clgc.2016.09.002. Epub 2016 Sep 19.
6
PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2.PI-RADS前列腺影像报告和数据系统：2015版，第2版
Eur Urol. 2016 Jan;69(1):16-40. doi: 10.1016/j.eururo.2015.08.052. Epub 2015 Oct 1.
7
Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT.¹⁸F-DCFPyL靶向PSMA的PET/CT对转移性透明细胞肾细胞癌的成像
Ann Nucl Med. 2015 Dec;29(10):877-82. doi: 10.1007/s12149-015-1017-z. Epub 2015 Aug 19.
8
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.18F-DCFBC（一种低分子量前列腺特异性膜抗原抑制剂）在转移性前列腺癌患者中的生物分布、肿瘤检测和辐射剂量学。
J Nucl Med. 2012 Dec;53(12):1883-91. doi: 10.2967/jnumed.112.104661.
9
LI-RADS: a case-based review of the new categorization of liver findings in patients with end-stage liver disease.LI-RADS：终末期肝病患者肝脏病变新分类的基于病例的综述。
Radiographics. 2012 Nov-Dec;32(7):1977-95. doi: 10.1148/rg.327125026.
10
[68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH.[68Ga]镓标记的前列腺特异性膜抗原（PSMA）配体作为诊断前列腺癌的优质正电子发射断层显像（PET）示踪剂：与18F-FECH的比较
Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):1085-6. doi: 10.1007/s00259-012-2069-0. Epub 2012 Feb 4.
Zotero 插件